Volume 6, Number 3—June 2000
Carbapenem-Resistant Pseudomonas aeruginosa with Acquired blavim Metallo-ß-Lactamase Determinants, Italy
Highlight and copy the desired format.
|EID||Rossolini G, Riccio ML, Cornaglia G, Pagani L, Lagatolla C, Selan L, et al. Carbapenem-Resistant Pseudomonas aeruginosa with Acquired blavim Metallo-ß-Lactamase Determinants, Italy. Emerg Infect Dis. 2000;6(3):312-313. https://dx.doi.org/10.3201/eid0603.000314|
|AMA||Rossolini G, Riccio ML, Cornaglia G, et al. Carbapenem-Resistant Pseudomonas aeruginosa with Acquired blavim Metallo-ß-Lactamase Determinants, Italy. Emerging Infectious Diseases. 2000;6(3):312-313. doi:10.3201/eid0603.000314.|
|APA||Rossolini, G., Riccio, M. L., Cornaglia, G., Pagani, L., Lagatolla, C., Selan, L....Fontana, R. (2000). Carbapenem-Resistant Pseudomonas aeruginosa with Acquired blavim Metallo-ß-Lactamase Determinants, Italy. Emerging Infectious Diseases, 6(3), 312-313. https://dx.doi.org/10.3201/eid0603.000314.|
To the Editor: Acquired metallo-ß-lactamase determinants in Pseudomonas aeruginosa and other major bacterial pathogens are of concern for development of antimicrobial drug resistance. The carbapenemase and extended-spectrum cephalosporinase activity of metallo-ß-lactamases, as well as their resistance to ß-lactamase inhibitors, may severely limit the antimicrobial agents active against bacterial strains that produce such enzymes (1,2). Antimicrobial chemotherapy may become ineffective against P. aeruginosa strains with a multidrug-resistant phenotype that have acquired a metallo-ß-lactamase determinant.
We recently described a new acquired metallo-ß-lactamase determinant, blaVIM, in a carbapenem-resistant P. aeruginosa clinical isolate (VR-143/97) from the University Hospital of Verona, Italy (3). This isolate was the index strain of an outbreak of blaVIM-positive P. aeruginosa, which was caused both by strains that were clonally related to VR-143/97 and by clonally unrelated strains (4). blaVIM is the second known metallo-ß-lactamase determinant that can spread among P. aeruginosa; the first was blaIMP, which was detected in the early 1990s in nosocomial isolates of various Enterobacteriaceae, P. aeruginosa, and other nonfastidious gram-negative nonfermenters from the Far East (1,2,5-7) and, recently, in an Acinetobacter baumannii clinical isolate from Italy (8). Although completely unrelated at the sequence level, blaVIM resembles blaIMP in being carried on an integron-borne mobile gene cassette and in encoding an enzyme (VIM-1) with broad substrate specificity (3). Because of these properties, blaVIM has the potential to become a dangerous resistance determinant.
An analysis of carbapenem-resistant P. aeruginosa from Italian hospitals since 1998 showed production of metallo-ß-lactamase, assayed as described (3), in five isolates from three hospitals in Italy. Two isolates (PPV-97 and PPV-108) were from the University Hospital of Pavia (PPV-97 was isolated in September 1998 from the urine of an inpatient in the neurosurgery department, and PPV-108 was isolated in November 1998 from a decubitus ulcer of an inpatient in the vascular surgery department); two (TS-832035 and TS-832347) were isolated in February 1999 from the University Hospital of Trieste (both from the blood of inpatients, in the intensive care unit and in the internal medicine department, respectively); and one (SAP-01/99) was isolated in September 1999 from the Rome University Hospital "Policlinico Umberto I" (from the blood of an inpatient in the vascular surgery department). Except for those from Pavia Hospital, where two departments share the same surgical unit, no epidemiologic relationship could be established among any of them or with those previously isolated in Verona (3,4).
The five isolates were highly resistant to carbapenems (MICs for imipenem and meropenem were >64 µg/ml) and to carbenicillin, ticarcillin, ticarcillin/clavulanate, piperacillin, piperacillin/tazobactam, mezlocillin, ciprofloxacin, gentamicin, tobramycin, and netilmicin. All five were also resistant to ceftazidime and cefepime, except for SAP-01/99, which had intermediate resistance to the above drugs. Some isolates retained susceptibility to aztreonam (PPV-97, TS-832035, and SAP-01/99) or amikacin (PPV-108, TS-832035, and TS-832347).
In a colony-blot hybridization assay (3), all the above isolates were recognized by a blaVIM-specific probe consisting of an amplicon that contained the entire blaVIM coding sequence (3). None were recognized by a probe specific for blaIMP and consisting of a 0.5-kb HindIII fragment from the blaIMP gene (8).
Our results indicate that circulation of carbapenem-resistant P. aeruginosa carrying blaVIM metallo-ß-lactamase determinants, originally detected in one Italian hospital (3-4), could soon become widespread. The detection in different hospitals of blaVIM-positive isolates that apparently were epidemiologically unrelated suggests that the environmental reservoir of blaVIM-containing strains is relatively broad and that this novel determinant has potential relevance for the emerging phenomenon of carbapenem resistance in P. aeruginosa. Since we did not sequence the blaVIM-related genes carried by the various isolates, we do not yet know whether they differ from that cloned from P. aeruginosa VR-143/97 (3). The five isolates described in this report are being characterized to ascertain their clonal relatedness and identify the sequences of their blaVIM-related determinants. The recent appearance of this and other acquired metallo-ß-lactamases among P. aeruginosa and other gram-negative pathogens in Europe (8-10) underlines the need for systematic surveillance to monitor the spread of similar resistance determinants.
This work was supported by grants no. FMRX-CT98-0232 from the European TMR Research Network on metallo-ß-lactamases and no. 9906404271 from MURST ex-40%.
- Livermore DM. Acquired carbapenemases. J Antimicrob Chemother. 1997;39:673–6.
- Rasmussen BA, Bush K. Carbapenem-hydrolyzing ß-lactamases. Antimicrob Agents Chemother. 1997;41:223–32.
- Lauretti L, Riccio ML, Mazzariol A, Cornaglia G, Amicosante G, Fontana R, Cloning and characterization of blaVIM, a new integron-borne metallo-ß-lactamase gene from a Pseudomonas aeruginosa clinical isolate. Antimicrob Agents Chemother. 1999;43:1584–90.
- Mazzariol A, Cornaglia G, Piccoli P, Lauretti L, Riccio ML, Rossolini GM, Carbapenem-hydrolyzing ß-lactamases in Pseudomonas aeruginosa. Eur J Clin Microbiol Infect Dis. 1999;18:455–6.
- Senda K, Arakawa Y, Nakashima K, Ito H, Ichiyama S, Shimokata K, Multifocal outbreaks of metallo-ß-lactamase-producing Pseudomonas aeruginosa resistant to broad-spectrum ß-lactams, including carbapenems. Antimicrob Agents Chemother. 1996;40:349–53.
- Lee K, Chong Y, Shin HB, Yong D. Rapid increase of imipenem-hydrolyzing Pseudomonas aeruginosa in a Korean hospital. In: Program and Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington: American Society for Microbiology; 1998. [Abstract E85].
- Koh TH, Babini GS, Woodford N, Sng LH, Hall LM, Livermore DM. Carbapenem-hydrolysing IMP-1 ß-lactamase in Klebsiella pneumoniae from Singapore. Lancet. 1999;353:2162.
- Cornaglia G, Riccio ML, Mazzariol A, Lauretti L, Fontana R, Rossolini GM. Appearance of IMP-1 metallo-ß-lactamase in Europe. Lancet. 1999;353:899–900.
- Woodford N, Palepou M-FI, Babini GS, Bates J, Livermore DM. Carbapenemase-producing Pseudomonas aeruginosa in the UK. Lancet. 1998;352:546–7.
- Cardoso O, Sousa JC, Leitâo R, Peixe L. Carbapenem-hydrolysing ß-lactamase from clinical isolates of Pseudomonas aeruginosa in Portugal. J Antimicrob Chemother. 1999;44:135.
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
- Page created: December 16, 2010
- Page last updated: December 16, 2010
- Page last reviewed: December 16, 2010
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)